Biogen Inc
SGO:BIIB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biogen Inc
SGO:BIIB
|
US |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
JP |
|
T
|
Trencor Ltd
JSE:TRE
|
ZA |
|
Uber Technologies Inc
TSX:UBER
|
US |
Intrinsic Value
Is BIIB undervalued or overvalued?
See the intrinsic value estimate for 
Biogen Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Biogen Does
Biogen is a biotechnology company that develops and sells medicines for serious diseases, with a long focus on conditions that affect the brain and nervous system. Its main products are prescription drugs for diseases such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, and certain rare neurological disorders. It also works on therapies for immunology and related areas, but its business is centered on specialty medicines that are prescribed by doctors rather than sold over the counter.
- Headquarters
- United States of America US
- Employees
- 7 500
- IPO date
- Sep 17, 1991
Biogen has a narrow economic moat
Patents and legal protection against competing copies prevent rivals from freely copying several of Biogen’s medicines, helping protect their sales and profits. That protection applies to individual drugs rather than the whole company, while competing treatments already give patients alternatives in important markets.
Read the full moat analysis
Revenue & Expenses Breakdown
Biogen Inc
Earnings Waterfall
Biogen Inc
The intrinsic value for Biogen Inc (BIIB) under the Base Case is hidden USD.
Compared with the current market price of 239.65 USD, the stock appears hidden.
